Stay updated on Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page.

Latest updates to the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check19 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.3, indicating a revision in the content.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check40 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check76 days agoChange DetectedThe web page has undergone significant content changes, including the removal of detailed information about a clinical trial involving Nivolumab for pediatric patients with relapsed solid tumors, while a new version number has been added.SummaryDifference44%
Stay in the know with updates to Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page.